Elevated D-dimer after infusion of alemtuzumab in patients with MS

Key clinical point: Alemtuzumab infusion in patients with multiple sclerosis (MS) is associated with the elevation of D-dimer level and the prolongation of prothrombin time (PT).

Major finding: Alemtuzumab infusion resulted in a significant elevation in D-dimer levels within the patient group (before vs after infusion, P = .00001) and also compared with control individuals (P = .00001). PT was also prolonged in patients receiving alemtuzumab post-infusion compared with the pre-infusion values (P = .00001).

Study details: In this study, coagulation parameters were analyzed in 13 patients with MS treated with alemtuzumab and 13 control individuals.

Disclosures: The study was supported by the MH CZ-DRO, Motol University Hospital, Prague, Czech Republic. Jana Libertinova, Eva Meluzinova, Eva Nema, Petra Rockova, Martin Elisak, Marko Petrzalka, and Hana Mojzisova reported receiving compensation for travel and/or speaker honoraria and consultant fees from multiple pharmaceutical companies. The remaining authors declared no conflict of interest. 

Citation: Libertinova J et al. Mult Scler. 2020 Feb 20. doi: 10.1177/1352458520904277. 

Key clinical point: Alemtuzumab infusion in patients with multiple sclerosis (MS) is associated with the elevation of D-dimer level and the prolongation of prothrombin time (PT).

Major finding: Alemtuzumab infusion resulted in a significant elevation in D-dimer levels within the patient group (before vs after infusion, P = .00001) and also compared with control individuals (P = .00001). PT was also prolonged in patients receiving alemtuzumab post-infusion compared with the pre-infusion values (P = .00001).

Study details: In this study, coagulation parameters were analyzed in 13 patients with MS treated with alemtuzumab and 13 control individuals.

Disclosures: The study was supported by the MH CZ-DRO, Motol University Hospital, Prague, Czech Republic. Jana Libertinova, Eva Meluzinova, Eva Nema, Petra Rockova, Martin Elisak, Marko Petrzalka, and Hana Mojzisova reported receiving compensation for travel and/or speaker honoraria and consultant fees from multiple pharmaceutical companies. The remaining authors declared no conflict of interest. 

Citation: Libertinova J et al. Mult Scler. 2020 Feb 20. doi: 10.1177/1352458520904277. 

Key clinical point: Alemtuzumab infusion in patients with multiple sclerosis (MS) is associated with the elevation of D-dimer level and the prolongation of prothrombin time (PT).

Major finding: Alemtuzumab infusion resulted in a significant elevation in D-dimer levels within the patient group (before vs after infusion, P = .00001) and also compared with control individuals (P = .00001). PT was also prolonged in patients receiving alemtuzumab post-infusion compared with the pre-infusion values (P = .00001).

Study details: In this study, coagulation parameters were analyzed in 13 patients with MS treated with alemtuzumab and 13 control individuals.

Disclosures: The study was supported by the MH CZ-DRO, Motol University Hospital, Prague, Czech Republic. Jana Libertinova, Eva Meluzinova, Eva Nema, Petra Rockova, Martin Elisak, Marko Petrzalka, and Hana Mojzisova reported receiving compensation for travel and/or speaker honoraria and consultant fees from multiple pharmaceutical companies. The remaining authors declared no conflict of interest. 

Citation: Libertinova J et al. Mult Scler. 2020 Feb 20. doi: 10.1177/1352458520904277.